PRINCETON, N.J., April 16, 2013 /PRNewswire/ -- Soligenix,
Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage
biopharmaceutical company focused on developing products for
serious inflammatory diseases and biodefense countermeasures where
there remains an unmet medical need, announced today that its Chief
Scientific Officer, Robert N. Brey,
PhD, will give a presentation on the stockpiling of biodefense
vaccines - technology innovation at the World Vaccine Congress
& Expo on Thursday, April 18, at
9:40 AM Eastern Standard Time.
The presentation will take place at the Gaylord National Resort
& Convention Center in National Harbor, MD.
The Soligenix presentation will be provided on the company's
website at http://www.soligenix.com/ following the conference.
For more information about the World Vaccine Congress &
Expo, please refer to the conference website at
http://www.terrapinn.com/2013/world-vaccine-congress-washington/index.stm.
About Soligenix, Inc.
Soligenix is a clinical stage biopharmaceutical company
developing products to treat serious inflammatory diseases where
there remains an unmet medical need, as well as developing several
biodefense vaccines and therapeutics. Soligenix is developing
proprietary formulations of oral BDP (beclomethasone
17,21-dipropionate) for the prevention/treatment of
gastrointestinal disorders characterized by severe inflammation,
including pediatric Crohn's disease (SGX203), acute radiation
enteritis (SGX201) and chronic Graft-versus-Host disease
(orBec®), as well as developing its novel innate defense
regulator (IDR) technology SGX942 for the treatment of oral
mucositis.
Through its BioDefense Division, Soligenix is developing
countermeasures pursuant to the Biomedical Advanced Research and
Development Authority (BARDA) Strategic Plan of 2011-2016 for
inclusion in the US government's Strategic National Stockpile.
Soligenix's lead biodefense products in development are a
recombinant subunit vaccine called RiVax™, which is designed to
protect against the lethal effects of exposure to ricin toxin and
VeloThrax™, a vaccine against anthrax exposure. RiVax™ has been
shown to be well tolerated and immunogenic in two Phase 1 clinical
trials in healthy volunteers. Both RiVax™ and VeloThrax™ are
currently the subject of a $9.4
million National Institute of Allergy and Infectious
Diseases (NIAID) grant supporting development of Soligenix's new
vaccine heat stabilization technology known as ThermoVax™.
Soligenix is also developing OrbeShield™ for the treatment of
gastrointestinal acute radiation syndrome (GI ARS) under a
$600,000 NIAID Small Business
Innovation Research (SBIR) grant. OrbeShield™ has previously
demonstrated statistically significant preclinical survival results
in two separate canine GI ARS studies funded by the NIH.
For further information regarding Soligenix, Inc., please visit
the Company's website at www.soligenix.com.
This press release contains forward-looking statements that
reflect Soligenix, Inc.'s current expectations about its future
results, performance, prospects and opportunities. Statements that
are not historical facts, such as "anticipates," "believes,"
"intends," "potential," or similar expressions, are forward-looking
statements. These statements are subject to a number of risks,
uncertainties and other factors that could cause actual events or
results in future periods to differ materially from what is
expressed in, or implied by, these statements. Soligenix cannot
assure you that it will be able to successfully develop or
commercialize products based on its technology, particularly in
light of the significant uncertainty inherent in developing
vaccines against bioterror threats, manufacturing and conducting
preclinical and clinical trials of vaccines, and obtaining
regulatory approvals, that product development and
commercialization efforts will not be reduced or discontinued due
to difficulties or delays in clinical trials or due to lack of
progress or positive results from research and development efforts,
that it will be able to successfully obtain any further grants and
awards, maintain its existing grants which are subject to
performance, enter into any biodefense procurement contracts with
the US Government or other countries, or that the US Congress may
not pass any legislation that would provide additional funding for
the Project BioShield program. These and other risk factors are
described from time to time in filings with the Securities and
Exchange Commission, including, but not limited to, Soligenix's
reports on Forms 10-Q and 10-K. Unless required by law, Soligenix
assumes no obligation to update or revise any forward-looking
statements as a result of new information or future events.
SOURCE Soligenix, Inc.